The role of hematopoietic stem cell niche in prostate cancer bone metastasis

Decker, Ann M.; Jung, Younghun; Cackowski, Frank C.; Taichman, Russell S.

doi:10.1016/j.jbo.2016.02.005

Cited by 27 publications

(14 citation statements)

References 36 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metastatic, and particularly castrate-resistant prostate cancer (CRPC), remain challenging to treat [ 23 ]. It is thought that the bone marrow microenvironment plays a pivotal role in promoting bone metastasis, possibly facilitating the transition to CRPC forms, and impacting on PCa cell drug response [ 24 – 27 ]. A barrier to understanding these interactions, in both drug development and testing, is the lack of in vitro models that adequately mimic aspects of the bone marrow microenvironment in a practical and high throughput manner.…”

Section: Discussionmentioning

confidence: 99%

Using high throughput microtissue culture to study the difference in prostate cancer cell behavior and drug response in 2D and 3D co-cultures

et al. 2018

View full text Add to dashboard Cite

BackgroundThere is increasing appreciation that non-cancer cells within the tumour microenvironment influence cancer progression and anti-cancer drug efficacy. For metastatic prostate cancer (PCa), the bone marrow microenvironment influences metastasis, drug response, and possibly drug resistance.MethodsUsing a novel microwell platform, the Microwell-mesh, we manufactured hundreds of 3D co-culture microtissues formed from PCa cells and bone marrow stromal cells. We used luciferase-expressing C42B PCa cells to enable quantification of the number of PCa cells in complex microtissue co-cultures. This strategy enabled us to quantify specific PCa cell growth and death in response to drug treatment, in different co-culture conditions. In parallel, we used Transwell migration assays to characterize PCa cell migration towards different 2D and 3D stromal cell populations.ResultsOur results reveal that PCa cell migration varied depending on the relative aggressiveness of the PCa cell lines, the stromal cell composition, and stromal cell 2D or 3D geometry. We found that C42B cell sensitivity to Docetaxel varied depending on culture geometry, and the presence or absence of different stromal cell populations. By contrast, the C42B cell response to Abiraterone Acetate was dependent on geometry, but not on the presence or absence of stromal cells.ConclusionIn summary, stromal cell composition and geometry influences PCa cell migration, growth and drug response. The Microwell-mesh and microtissues are powerful tools to study these complex 3D interactions.Electronic supplementary materialThe online version of this article (10.1186/s12885-018-4473-8) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Using high throughput microtissue culture to study the difference in prostate cancer cell behavior and drug response in 2D and 3D co-cultures

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Most cancer-related deaths are caused by metastatic spread rather than the primary tumour. Breast, prostate, renal, lung and thyroid cancers preferentially metastasise to the bone ( Virk and Lieberman, 2007 ), and it is postulated that disseminated cancer cells follow the cytokine signalling pathways that are usually used by the HSCs to home to the bone marrow microenvironment ( Decker et al, 2016 ; Reagan and Rosen, 2016 ). Once there, the disseminated cancer cells lie dormant or interact with the resident bone cells to stimulate growth factor release and other pro-tumorigenic signals ( Ottewell, 2016 ).…”

Section: Humanised Bone Approaches For Disease Modellingmentioning

confidence: 99%

Animal models for bone tissue engineering and modelling disease

McGovern

Griffin

Hutmacher

2018

Disease Models &Amp; Mechanisms

213

172

View full text Add to dashboard Cite

Tissue engineering and its clinical application, regenerative medicine, are instructing multiple approaches to aid in replacing bone loss after defects caused by trauma or cancer. In such cases, bone formation can be guided by engineered biodegradable and nonbiodegradable scaffolds with clearly defined architectural and mechanical properties informed by evidence-based research. With the ever-increasing expansion of bone tissue engineering and the pioneering research conducted to date, preclinical models are becoming a necessity to allow the engineered products to be translated to the clinic. In addition to creating smart bone scaffolds to mitigate bone loss, the field of tissue engineering and regenerative medicine is exploring methods to treat primary and secondary bone malignancies by creating models that mimic the clinical disease manifestation. This Review gives an overview of the preclinical testing in animal models used to evaluate bone regeneration concepts. Immunosuppressed rodent models have shown to be successful in mimicking bone malignancy via the implantation of human-derived cancer cells, whereas large animal models, including pigs, sheep and goats, are being used to provide an insight into bone formation and the effectiveness of scaffolds in induced tibial or femoral defects, providing clinically relevant similarity to human cases. Despite the recent progress, the successful translation of bone regeneration concepts from the bench to the bedside is rooted in the efforts of different research groups to standardise and validate the preclinical models for bone tissue engineering approaches.

show abstract

“…It is worth noting that normal bone houses the hematopoietic stem cell (HSC) niche, comprised by hematopoietic and mesenchymal cell populations, which provide homing signals to HSCs and regulate HSC selfrenewal (Taichman et al 2010). It has been suggested that DTCs can precondition the metastatic niche and compete with and occupy the HSC niche to facilitate metastasis (Decker et al 2016).…”

Section: Cancer Progression To Established Bone Metastasesmentioning

confidence: 99%

“…The mechanism that makes cancer cells leave the dormant state and start growing is ill-defined and a subject of intense study. It has been proposed that there are signals and factors from the metastatic/HSC niche, including FGF2, that can play a role in exiting dormancy (Decker et al 2016).…”

Section: Cancer Progression To Established Bone Metastasesmentioning

confidence: 99%

Fibroblast growth factors signaling in bone metastasis

Labanca

Vázquez

Corn

et al. 2020

Endocrine-Related Cancer

View full text Add to dashboard Cite

Many solid tumors metastasize to bone, but only prostate cancer has bone as a single, dominant metastatic site. Recently, the FGF axis has been implicated in cancer progression in some tumors and mounting evidence indicate that it mediates prostate cancer bone metastases. The FGF axis has an important role in bone biology and mediates cell-to-cell communication. Therefore, we discuss here basic concepts of bone biology, FGF signaling axis, and FGF axis function in adult bone, to integrate these concepts in our current understanding of the role of FGF axis in bone metastases.

show abstract

The role of hematopoietic stem cell niche in prostate cancer bone metastasis

Cited by 27 publications

References 36 publications

Using high throughput microtissue culture to study the difference in prostate cancer cell behavior and drug response in 2D and 3D co-cultures

Using high throughput microtissue culture to study the difference in prostate cancer cell behavior and drug response in 2D and 3D co-cultures

Animal models for bone tissue engineering and modelling disease

Fibroblast growth factors signaling in bone metastasis

Contact Info

Product

Resources

About